Compare ADPT & AROC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ADPT | AROC |
|---|---|---|
| Founded | 2009 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 5.3B |
| IPO Year | 2019 | 2007 |
| Metric | ADPT | AROC |
|---|---|---|
| Price | $27.73 | $25.65 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 6 |
| Target Price | $33.86 | ★ $42.71 |
| AVG Volume (30 Days) | ★ 2.1M | 1.8M |
| Earning Date | 11-04-2026 | 11-02-2026 |
| Dividend Yield | N/A | ★ 3.43% |
| EPS Growth | 63.89 | ★ 74.29 |
| EPS | N/A | ★ 1.27 |
| Revenue | $276,976,000.00 | ★ $1,489,818,000.00 |
| Revenue This Year | $10.85 | $0.20 |
| Revenue Next Year | $21.60 | $9.33 |
| P/E Ratio | ★ N/A | $21.09 |
| Revenue Growth | ★ 54.77 | 28.70 |
| 52 Week Low | $12.00 | $22.91 |
| 52 Week High | $32.21 | $42.23 |
| Indicator | ADPT | AROC |
|---|---|---|
| Relative Strength Index (RSI) | 49.06 | 35.02 |
| Support Level | $24.02 | N/A |
| Resistance Level | $29.92 | $37.33 |
| Average True Range (ATR) | 1.71 | 1.37 |
| MACD | -0.09 | -0.21 |
| Stochastic Oscillator | 31.91 | 0.92 |
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
Archrock Inc is an energy infrastructure company focused on midstream natural gas compression. It is a provider of natural gas compression services, based on total compression fleet horsepower, to customers across the United States and a supplier of aftermarket services to customers that own compression equipment. The company operates through two segments: contract operations and aftermarket services. The contract operations segment includes designing, sourcing, owning, installing, operating, servicing, repairing, and maintaining its owned fleet of natural gas compression equipment, and generates the maximum revenue. The aftermarket services segment provides operations, maintenance, overhaul, and reconfiguration services, and sales of parts and components.